Navigation Links
AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma
Date:6/19/2012

esign of its future clinical trials. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "will," "may," "potential," "anticipated," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks associated with the timing and success of preclinical studies and clinical trials and the potential problems that may arise in the research and development and approval process, market competition, Rigel's need for additional capital, risks associated with Rigel's corporate partnerships and collaborations, including risks that if conflicts arise between Rigel's and its corporate partners, the clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated, as well as other risks detailed from time to time in Rigel's reports with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2012. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Rigel Contacts:
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
Phone: 650.430.3777
Email: susan@alchemyemail.com

AstraZeneca Media Enquiries:
Andrea Conners, +44 (0)20 7604 8221 On-site at BIO
Chris Sampson, +32 47
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
2. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
3. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
4. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
5. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
6. ResearchMoz: Oxygen Concentrator Market Shares, Strategies and Forecasts, Worldwide, 2012 to 2018
7. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
8. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
9. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
10. ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
11. HistoRx Licenses Melanoma Assay from Yale University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 The Conferee Networking committee is ... Conferee Networking. These two-hour sessions provide a unique networking ... resolve problems, discuss new techniques, or brainstorm new ideas ... a topic for consideration is August 31, 2014, and ... Conferee Networking committee will review the topics, and status ...
(Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... Nile Therapeutics,Inc. (OTC Bulletin Board: SPDU.OB), announced ... present at the Biotechnology Industry,Organization (BIO) Investor Forum ... Time at The Palace Hotel in San Francisco, ... and an update on its clinical,development programs, including ...
... Oct. 2 /PRNewswire/ - Respironics, Inc. (Nasdaq:,RESP) today ... outstanding shares,of Apollo Light Systems, Inc., a 20-year-old, ... therapy systems for melatonin suppression and,circadian rhythm sleep ... is located in American Fork, Utah and has ...
... 2 Monitorforhire.com, the,fastest source for hiring ... faster. The company has added a mobile ... immediately to work requests via,PDA or cell ... Freedman, president of monitorforhire.com says that adding ...
Cached Biology Technology:Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum 2Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum 3Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 2Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 3
(Date:7/27/2014)... and fungi can evade treatment by acquiring mutations in ... permanent mutations were once thought to be the only ... study has shown that microorganisms can use a temporary ... to gain the benefits of drug resistance without the ... a fungus called Mucor circinelloides, it is likely to ...
(Date:7/27/2014)... In an age of "big data," a single computer ... tasks must instead be distributed across a cluster of ... how Facebook and Google mine your web history to ... Netflix recommend your next favorite book or movie. But ... , New technologies for monitoring brain activity are generating ...
(Date:7/25/2014)... lived on the land now called California, and many ... of plants they used for food, fuel, tools, and ... desired habitat and natural resources. , Frank Lake, an ... will lead a field trip to the ... of America,s 99th Annual Meeting, in Sacramento, Cal. this ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... as we grow older, our bones become more brittle and ... of mass is a major reason for older bones fracturing ... on slowing down this loss. However, new research from scientists ... Laboratory (Berkeley Lab) shows that at microscopic dimensions, the age-related ...
... Winston-Salem, N.C. -- New research from Wake Forest ... electronics by developing, for the first time, an ... electrical properties, and inexpensive to produce. ... of physics at Wake Forest, her graduate students ...
... 2011 Neurotechnology , a provider ... the availability of SentiSight 3.0 , a Software ... version adds shape-based recognition and offers enhanced local-feature-based recognition ... also includes enhanced tracking of fast moving objects and ...
Cached Biology News:The brittleness of aging bones -- more than a loss of bone mass 2The brittleness of aging bones -- more than a loss of bone mass 3Flexible electronics hold promise for consumer applications 2SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 2SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 3SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 4
... AviTag E. coli Biotinylation Kit, Plasmid is designed ... E. coli expression kits. (Cat. No. 3 186 ... kit provides vectors for the easy introduction of ... expressed protein can be enzymatically mono-biotinylated by E. ...
... The ubiquitin-proteasome pathway is the major ... eukaryotic cells, where it catalyzes the ... and the rapid elimination of proteins ... 1998; Hochstrasser 1996). The critical protease ...
... technology enables sensitive, fast and specific detection ... Short hybridisation time ( ... chromosome spreads Multiplex capability Available ... Probes available with different labels. ...
... * Source rat ... T25 plated cells $550.00, * ... 120 population doublings, * This ... complete ,growth medium M55007-08 and ...
Biology Products: